Home Cart Sign in  
Chemical Structure| 61019-05-4 Chemical Structure| 61019-05-4

Structure of 61019-05-4

Chemical Structure| 61019-05-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 61019-05-4 ]

CAS No. :61019-05-4
Formula : C10H11NO
M.W : 161.20
SMILES Code : COC1=CC2=C(NC=C2)C(C)=C1
MDL No. :MFCD09027022
InChI Key :YGPVRHHGKCQSIL-UHFFFAOYSA-N
Pubchem ID :12338917

Safety of [ 61019-05-4 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P280-P305+P351+P338-P304+P340-P405-P501

Computational Chemistry of [ 61019-05-4 ] Show Less

Physicochemical Properties

Num. heavy atoms 12
Num. arom. heavy atoms 9
Fraction Csp3 0.2
Num. rotatable bonds 1
Num. H-bond acceptors 1.0
Num. H-bond donors 1.0
Molar Refractivity 49.76
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

25.02 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.05
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.38
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.48
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.53
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.98
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.28

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.83
Solubility 0.24 mg/ml ; 0.00149 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.55
Solubility 0.458 mg/ml ; 0.00284 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.79
Solubility 0.0263 mg/ml ; 0.000163 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.59 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.28

Application In Synthesis of [ 61019-05-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 61019-05-4 ]

[ 61019-05-4 ] Synthesis Path-Downstream   1~35

  • 1
  • [ 74798-63-3 ]
  • [ 61019-05-4 ]
  • 3
  • [ 61019-05-4 ]
  • [ 73430-27-0 ]
  • 5-methoxy-7-methyl-3-(2-nitrovinyl)indole [ No CAS ]
  • 4
  • [ 102-50-1 ]
  • [ 61019-05-4 ]
  • 5
  • [ 61019-05-4 ]
  • [ 108-94-1 ]
  • 3-cyclohexyl-5-methoxy-7-methyl-1H-indole [ No CAS ]
  • 6
  • [ 61019-05-4 ]
  • [ 24424-99-5 ]
  • tert-butyl 5-methoxy-7-methyl-1H-indole-1-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
With dmap; triethylamine; In dichloromethane; at 20℃; for 16.0h;Inert atmosphere; To a solution of <strong>[61019-05-4]5-methoxy-7-methyl-1H-indole</strong> (CAS: 61019-05-4, 9.69 g, 60.1 mmol) inCH2CI2 (200 mL) at room temperature was added Boc2O (19.54 ml, 84 mmol), DMAP (0.734 g, 6.01 mmol), and Et3N (10.05 ml, 72.1 mmol). The mixture was then stirred for 16h. The reaction wasdiluted with CH2CI2 and saturated NH4CI. The aqueous phase was extracted three times withCH2CI2. The organic phase was washed with brine, dried over Na2504, filtered, and concentrated.The resulting residue was purified by silica gel flash column chromatography (EtOAc/heptanes) toprovide the title compound. MS (ESl+) m/z 262.2 (M+H).
  • 7
  • [ 61019-05-4 ]
  • (±)-tert-butyl 4-(rel-(2S,4S)-(4-ethoxy-2-(4-(methoxycarbonyl)phenyl)piperidin-1-yl)methyl)-5-methoxy-7-methyl-1H-indole-1-carboxylate [ No CAS ]
  • 8
  • [ 61019-05-4 ]
  • (±)-tert-Butyl 5-methoxy-4-((2-(4-(methoxycarbonyl)naphthalen-1-yl)piperidin-1-yl)methyl)-7-methyl-1H-indole-1-carboxylate [ No CAS ]
  • 9
  • [ 61019-05-4 ]
  • (±)-tert-butyl 5-methoxy-7-methyl-4-(2,2,2-trifluoro-1-hydroxyethyl)-1H-indole-1-carboxylate [ No CAS ]
  • 10
  • [ 61019-05-4 ]
  • methyl 4-(2S)-(1-(2,2,2-trifluoro-1-(5-methoxy-7-methyl-1H-indol-4-yl)ethyl)piperidin-2-yl)benzoate [ No CAS ]
  • 11
  • [ 61019-05-4 ]
  • (±)-tert-butyl 5-methoxy-4-((rel-(2S,4R)-2-(4-(methoxycarbonyl)phenyl)-4-methylpiperidin-1-yl)methyl)-7-methyl-1H-indole-1-carboxylate [ No CAS ]
  • 12
  • [ 61019-05-4 ]
  • tert-butyl 5-methoxy-4-(((2S,4R)-2-(4-(methoxycarbonyl)phenyl)-4-methylpiperidin-1-yl)methyl)-7-methyl-1H-indole-1-carboxylate [ No CAS ]
  • tert-butyl 5-methoxy-4-(((2R,4S)-2-(4-(methoxycarbonyl)phenyl)-4-methylpiperidin-1-yl)methyl)-7-methyl-1H-indole1-carboxylate [ No CAS ]
  • 13
  • [ 61019-05-4 ]
  • (±)-tert-butyl 5-methoxy-4-(rel-(2S,4S)-(4-methoxy-2-(4-(methoxycarbonyl)phenyl)piperidin-1-yl)methyl)-7-methyl-1H-indole-1-carboxylate [ No CAS ]
  • 14
  • [ 61019-05-4 ]
  • tert-butyl 5-methoxy-4-((2R,4R)-(4-methoxy-2-(4-(methoxycarbonyl)phenyl)piperidin-1-yl)methyl)-7-methyl-1H-indole-1-carboxylate [ No CAS ]
  • 15
  • [ 61019-05-4 ]
  • tert-butyl 5-methoxy-4-((2S,4S)-(4-methoxy-2-(4-(methoxycarbonyl)phenyl)piperidin-1-yl)methyl)-7-methyl-1H-indole-1-carboxylate [ No CAS ]
  • 16
  • [ 61019-05-4 ]
  • (±)-methyl 4-(rel-(2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoate [ No CAS ]
  • 17
  • [ 61019-05-4 ]
  • methyl 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoate [ No CAS ]
  • methyl 4-((2R,4R)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoate [ No CAS ]
  • 18
  • [ 61019-05-4 ]
  • (+)-4-((2S,4R)-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-4-methylpiperidin-2-yl)benzoic acid [ No CAS ]
  • 19
  • [ 61019-05-4 ]
  • 4-((2S,4R)-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-4-methyl piperidin-2-yl)benzoic acid phosphate salt [ No CAS ]
  • 20
  • [ 61019-05-4 ]
  • (-)-4-((2S,4S)-4-methoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid [ No CAS ]
  • 21
  • [ 61019-05-4 ]
  • 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid triflouroacetate salt [ No CAS ]
  • 22
  • [ 61019-05-4 ]
  • (+)-4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)-N-(methylsulfonyl)benzamide [ No CAS ]
  • 23
  • [ 61019-05-4 ]
  • Ethyl 4-((2S,4R)-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-4-methylpiperidin-2-yl)benzoate [ No CAS ]
  • 24
  • [ 61019-05-4 ]
  • tert-butyl 4-formyl-5-methoxy-7-methyl-1H-indole-1-carboxylate [ No CAS ]
  • 25
  • [ 61019-05-4 ]
  • tert-Butyl-4-(hydroxymethyl)-5-methoxy-7-methyl-1H-indole-1-carboxylate [ No CAS ]
  • 26
  • [ 61019-05-4 ]
  • [ 79893-97-3 ]
  • 5-methoxy-7-methyl-1-(3-methyl-4,6-diphenylpyridin-2-yl)-1H-indole [ No CAS ]
  • 27
  • [ 61019-05-4 ]
  • methyl 1-acetyl-2-(p-tolyl)cyclopropane-1-carboxylate [ No CAS ]
  • methyl 6-methoxy-1,8-dimethyl-4-(p-tolyl)-4,9-dihydro-3H-carbazole-2-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
68% With toluene-4-sulfonic acid; In ethanol; at 60℃; for 0.333333h; General procedure: In a typical reaction, DAC (0.20 mmol) was mixed with indole (0.20 mmol) and PTSA (10 mol%) in ethanol (1.0 mL). The mixture was then stirred at 60C for 20 min. After reaction, the mixture was cooled to room temperature, and the product was obtained by isolation with preparative TLC (eluting solution: petroleum ether/ethyl acetate=5/1 (v/v)). Tests for substrate scope were all performed with an analogous procedure. Large scale synthesis was also performed in a similar procedure. The product was isolated by silica column chromatography (eluting solution: petroleum ether/ethyl acetate=8/1 (v/v)).
  • 28
  • [ 61019-05-4 ]
  • [ 82469-39-4 ]
  • 1-(6-methoxy-1,8-dimethyl-9H-carbazol-2-yl)ethanone [ No CAS ]
  • 29
  • [ 61019-05-4 ]
  • 5-methoxy-1-(5-methoxy-7-methylindolin-3-yl)-7-methyl-1H-indole [ No CAS ]
  • 30
  • [ 61019-05-4 ]
  • [ 102-92-1 ]
  • C19H17NO2 [ No CAS ]
YieldReaction ConditionsOperation in experiment
In toluene; at 20℃; for 1.0h; To a 250 ml round bottom flask was added 7-methyl-5-methoxy-lH-indole (50 mmol)Add 100 ml of toluene to mix it,Further addition of cinnamoyl chloride (60 mmol)Room temperature reaction for 1 hour,After the compound has been completely precipitated,Phenylhydrazine (60 mmol) was added,Heated to 105 C with a heating jacket,Placed on a magnetic stirrer,The reaction was heated under reflux for 6 hours,Reaction process constantly point observation,After the reaction is complete, the heating is stopped and the condensing unit is removed.The reaction solution was distilled and concentrated, and the product was isolated by column chromatography.The crude product was recrystallized from an ethanol-water solution, dried,The product was obtained (pale pink solid 12.71 g, yield 80.2%).
  • 31
  • [ 61019-05-4 ]
  • [ 123-54-6 ]
  • [ 78-98-8 ]
  • 3-acetyl-4-(5-methoxy-7-methyl-1H-indol-3-yl)hexane-2,5-dione [ No CAS ]
  • 32
  • [ 4360-63-8 ]
  • [ 61019-05-4 ]
  • [ 98-86-2 ]
  • 3-methoxy-1-methyl-8-phenyl-9H-carbazole [ No CAS ]
  • 33
  • [ 61019-05-4 ]
  • [ 68-12-2 ]
  • C11H11NO2 [ No CAS ]
YieldReaction ConditionsOperation in experiment
60% Oxalyl chloride (0.17 mL, 1.93 mmol) was added dropwise via syringe over 1 min to DMF (1.5 mL) in a vial charged with a magnetic stir bar under N2 at 0 C. After ~30 min, <strong>[61019-05-4]5-methoxy-7-methyl-1H-indole</strong> (342 mg, 2.123 mmol) was added dropwise via syringe over ~30 s as a solution in DMF (2 mL). The reaction was allowed to warm to room temperature and stir overnight, after which 1 N NaOH (2 mL) was added dropwise via syringe over 30 s. The reaction was then heated to 100 oC for 20 min, after which it was cooled to room temperature. After 28 h of total reaction time, the mixture was diluted with H2O (15 mL) and DCM (20 mL). The organic layer was separated, and the aqueous layer was washed with DCM (10 mL). The combined organic layers were washed with H2O (2 × 15 mL) and brine (10 mL), dried with Na2SO4, filtered, and concentrated in vacuo to provide a dark red crude residue. The crude material was purified via flash chromatography on silica (24 g column, 0-60% EtOAc/heptane) to afford 300 mg (82% yield) of 13 as a pale yellow solid. 1H NMR (400 MHz, DMSO-d6) delta ppm 12.27 - 11.84 (m, 1H), 9.89 (s, 1H), 8.20 (d, J = 3.30 Hz, 1H), 7.41 (d, J = 2.45 Hz, 1 H), 6.71 (dd, J = 2.32, 0.73 Hz, 1H), 3.76 (s, 3H), 2.48 - 2.43 (m, 3H); LCMS m/z = 190.2 ([M+H]+), tR = 1.00 min (method A).
  • 34
  • [ 61019-05-4 ]
  • C20H22ClN5O*C2HF3O2 [ No CAS ]
  • 35
  • [ 61019-05-4 ]
  • C24H38N4OS [ No CAS ]
 

Historical Records

Technical Information

Categories